^
    3d
    Exploration of the Efficacy and Safety of metronomic chemotherapy with vinorelbine capsules combined with third-generation EGFR-TKI as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations (ChiCTR2500115674)
    P=N/A, N=66, Not yet recruiting, Beijing hospital; Beijing hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Ameile (aumolertinib) • vinorelbine tartrate • Ivesa (firmonertinib) • simmitinib (SYHA1817)
    3d
    An Open-Label, Single-Arm, Exploratory Phase Ⅱ Clinical Study of Almonertinib Combined with Vinorelbine Tartrate Soft Capsules in the Treatment of Elderly Patients with Advanced NSCLC Progressed after Third-Generation EGFR-TKI Therapy (ChiCTR2600116503)
    P2, N=100, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital; Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Ameile (aumolertinib) • vinorelbine tartrate
    7d
    TROPION-Lung12: A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features (clinicaltrials.gov)
    P3, N=24, Active, not recruiting, AstraZeneca | N=660 --> 24 | Trial completion date: Jan 2035 --> Jun 2027 | Trial primary completion date: May 2033 --> Jun 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    cisplatin • carboplatin • pemetrexed • etoposide IV • vinorelbine tartrate • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936)
    12d
    FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer (clinicaltrials.gov)
    P3, N=350, Active, not recruiting, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate
    20d
    Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] (clinicaltrials.gov)
    P3, N=1280, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Aug 2035 --> Dec 2027
    Trial completion date
    |
    cisplatin • Tecentriq (atezolizumab) • gemcitabine • docetaxel • pemetrexed • vinorelbine tartrate
    22d
    THIO-104: A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC (clinicaltrials.gov)
    P3, N=300, Recruiting, Maia Biotechnology | Not yet recruiting --> Recruiting | Trial completion date: Jul 2027 --> Dec 2027 | Trial primary completion date: Jul 2026 --> Jul 2027
    Enrollment open • Trial completion date • Trial primary completion date • IO biomarker
    |
    gemcitabine • docetaxel • Libtayo (cemiplimab-rwlc) • vinorelbine tartrate • ateganosine (THIO)
    24d
    Metronomic 5-Fluorouracil and Vinorelbine Reduce Cancer Stemness and Modulate EZH2/NOTCH-1/STAT3 Signaling in Triple-Negative Breast Cancer Spheroids. (PubMed, Int J Mol Sci)
    Unlike STD, which partially and transiently reduced stemness markers, mCHT achieved sustained suppression, indicating preferential targeting of therapy-resistant CSCs. These results indicate mCHT as a promising strategy for specifically aiming at the CSC-like compartment in TNBC, underscoring a therapeutic approach that reprograms key epigenetic networks and overcomes resistance to treatment.
    Journal
    |
    NOTCH1 (Notch 1) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD44 (CD44 Molecule)
    |
    5-fluorouracil • vinorelbine tartrate
    29d
    AZALEA: Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients (clinicaltrials.gov)
    P2, N=45, Recruiting, European Institute of Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression
    |
    VENTANA PD-L1 (SP142) Assay
    |
    Tecentriq (atezolizumab) • cyclophosphamide • vinorelbine tartrate
    29d
    Inetetamab-Based Regimens for Patients with HER2-Positive Metastatic Breast Cancer: A Real-World Retrospective Study. (PubMed, Breast Cancer (Dove Med Press))
    The most frequently combined chemotherapy was vinorelbine (83/90,92.2%). The most frequently concomitant targeted drug was pyrotinib (70/90,77.8%)...Inetetamab offers a promising option and a manageable safety profile for HER2-positive MBC who pretreated with multiple-line therapies. Meanwhile, inetetamab plus small-molecule TKIs regimens shows good anti-tumor efficacy for MBC with brain metastases, which deserves further validation in a larger group trial.
    Retrospective data • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Irene (pyrotinib) • vinorelbine tartrate • Cipterbin (inetetamab)
    1m
    Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study. (PubMed, Ann Oncol)
    TROPION-Breast01 met its dual primary endpoint of PFS by BICR. While there was no statistically significant improvement in the dual primary endpoint of OS with Dato-DXd versus ICC, subsequent ADC treatment may have affected OS results. The totality of efficacy and safety data support Dato-DXd as a new treatment option for patients with previously treated, inoperable/metastatic HR+/HER2‒ breast cancer.
    P3 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • EGFR positive • HR positive + HER-2 negative
    |
    gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Datroway (datopotamab deruxtecan-dlnk)
    2ms
    BRIDGE: Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (clinicaltrials.gov)
    P2, N=10, Terminated, Mario Negri Institute for Pharmacological Research | Trial completion date: Jun 2026 --> Jan 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jan 2025; Low enrolment rate
    Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • vinorelbine tartrate
    2ms
    Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=192, Recruiting, Sun Yat-sen University | Enrolling by invitation --> Recruiting
    Enrollment status
    |
    gemcitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • utidelone IV (UTD1)